Autonomic Technologies(R) Opens New International Headquarters to Further Drive Leadership in the Field of Neurostimulation in Headache

MUNICH, GERMANY--(Marketwired - Nov 25, 2015) - Autonomic Technologies® announces the opening of a new international headquarters in Munich, Germany. The new office is the latest step in the company's strategic focus of expanding commercialization in international markets. With the number of patients treated annually growing dramatically and implantations performed in nine European countries this year, ATI is moving full speed into the commercial expansion of the Pulsante® therapy for the treatment of cluster headache.

The commercial success is also reflected by the recent build-up of ATI's international presence. "With the significant increase in the number of employees outside the US, the new international headquarters will have all key functions under one roof and increase our footprint in Europe," comments Karl Schweitzer, President International at Autonomic Technologies. "The office in Munich is ideally located to further build on our leadership position in the growing field of neurostimulation in headache."

The Pulsante® Microstimulator that offers on-demand stimulation of the Sphenopalatine Ganglion (SPG) that is known to play a critical role in cluster headache, sets new standards in neuromodulation and brings new hope to patients suffering from the debilitating effects of cluster headache. The minimally invasive device is the first and only neuromodulation therapy that provides acute benefit along with a noted reduction in cluster headaches in some patients without any systemic side effects, potentially positioning Pulsante® early in the treatment pathway. Backed by long-term, excellent clinical data, Pulsante® has received the CE mark for both chronic and episodic cluster headache.

Pulsante® provides on-demand, direct, local stimulation to the SPG, a nerve bundle located behind the nose that is known to play a major role in severe headaches. As the energy is transmitted wirelessly through a hand-held remote controller, the Pulsante® Microstimulator does not require a battery. This design reduces the need for multiple procedures to replace depleted batteries, improving the overall efficiency of the treatment and improving patient satisfaction. The miniaturized device is inserted through the patient's gum using a minimally invasive technique that leaves no visible scars.

About Autonomic Technologies
Autonomic Technologies, Inc. (ATI®) is a medical device company headquartered in the San Francisco Bay Area with offices in Germany and Switzerland, focused on the development and commercialization of innovative therapies for the treatment of autonomic disorders, particularly severe headache. The company's initial product, the Pulsante® Microstimulator, is CE marked in Europe for the treatment of cluster headache. The device (also known as Autonomic Technologies, Inc. (ATI®) Neurostimulation System) is under an IDE study in the US for the treatment of chronic cluster headache. For more information, please visit: www.pulsante.eu or www.ati-spg.com.